Amanta Healthcare MD, chairman, board of directors and AGM
NSE: AMANTABSE: 544502Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹164.88.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹633 Cr1,889th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 5 Aug 2026
- 43.1
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹2.63 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 36.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 2.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record. The filing of 5 Aug 2026
- 6.7%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹2.63 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 7.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 5 Aug 2026
- 9.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 1.06
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,21,12048.9% delivered
Amanta Healthcare board of directors
At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
- Chairperson and managing directorBhavesh Girishbhai Patel
- Company Secretary and Compliance OfficerNikhita Dinodia
6 directors3 independent1 executive2 non-executive
- Bhavesh Girishbhai Patel · Chairperson and managing directorExecutive · joined Dec 1994 · 1 listed board · 1 committee seat
- Nimesh P PatelNon-executive · joined Dec 2020 · 1 listed board · 1 committee seat, 1 as chair
- Kshitij Manubhai PatelIndependent · joined Aug 2023 · reappointed Aug 2023 · 38 months as independent · 1 listed board · 1 as independent · 2 committee seats, 1 as chair
- Anjali Nirav ChoksiIndependent · joined May 2024 · reappointed May 2024 · 29 months as independent · 1 listed board · 1 as independent · 2 committee seats
- Nitin JainIndependent · joined Aug 2024 · reappointed Aug 2024 · 26 months as independent · 2 listed boards · 2 as independent · 2 committee seats
- Pratik Punamchand GandhiNon-executive · joined Aug 2024 · 1 listed board
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 5 Aug 20266 of 6 present3 independent · 77 days in between
- 19 May 20266 of 6 present3 independent
Audit Committee
Chair Kshitij Manubhai Patel
Bhavesh Girishbhai Patel, Anjali Nirav Choksi
- 5 Aug 20263 of 3 present2 independent · 77 days in between
- 19 May 20263 of 3 present2 independent
Nomination and remuneration committee
Chair Kshitij Manubhai Patel
Nimesh P Patel, Anjali Nirav Choksi
- 5 Aug 20263 of 3 present2 independent · 77 days in between
- 19 May 20263 of 3 present2 independent
Stakeholders Relationship Committee
Chair Nimesh P Patel
Kshitij Manubhai Patel, Anjali Nirav Choksi
- 5 Aug 20263 of 3 present2 independent · 77 days in between
- 19 May 20263 of 3 present2 independent
Corporate Social Responsibility Committee
Chair Bhavesh Girishbhai Patel
Nimesh P Patel, Kshitij Manubhai Patel, Anjali Nirav Choksi
- 19 May 20264 of 4 present2 independent
IPO Committee
Chair Bhavesh Girishbhai Patel
Nimesh P Patel, Kshitij Manubhai Patel
No meeting listed in the filing.
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- Price Waterhouse Chartered Accountants LLPPeer-review certificate valid to Nov 2026
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Amanta Healthcare AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Amanta Healthcare share news and announcements
Annual general meeting, 16 Sep 2026
12,548 shareholders on the register on 9 Sep 2026; present: 1 promoter and 33 others; votes counted by Mr. Kashyap R. Mehta / M/s. Kashyap R. Mehta & Partners.The company's voting result (opens in a new tab)
- To receive, consider and adopt the Audited Financial Statements of the Company for the Financial Year ended 31st March 2026 and the Reports of the Board of Directors and Statutory Auditors thereon.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 64.39% · promoters 89.75% · institutions 42.23% · other public 8.21%
- To appoint a director in place of Shri Nimesh P Patel (OIN:09044772), who retires by rotation, and being eligible offers himself for re-appointment.Ordinary99.93% for0.07% against
Against: promoters 0.00% · institutions 0.86% · other public 0.02%
Turnout: all 64.39% · promoters 89.75% · institutions 42.23% · other public 8.21%
- To appoint the Secretarial Auditor of the company for a term of 5 consecutive years.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 64.39% · promoters 89.75% · institutions 42.23% · other public 8.21%
- To ratify the remuneration of cost auditor for FY 2026-27.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.02%
Turnout: all 64.39% · promoters 89.75% · institutions 42.23% · other public 8.21%
- To approve the revision in the remuneration payable to Shri Bhavesh Girishbhai Patel, Managing Director of the Company.SpecialPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.03%
Turnout: all 48.09% · promoters 64.19% · institutions 42.23% · other public 8.21%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- No
- The chair is related to the managing director
- Yes
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.
How money raised was used
Reported for the quarter to Jun 2026.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere |
|---|---|---|---|---|---|
| Public IssuesSep 2025, checked by CRISIL Ratings Limited | 126.00 | Funding capital expenditure requirements for civil construction work and towards purchase of equipment, plant and machinery for setting up new manufacturing line of SteriPort at Hariyala, Kheda, Gujarat. | 70.00 | 60.05 | No |
| Public IssuesSep 2025, checked by CRISIL Ratings Limited | 126.00 | Funding capital expenditure requirements towards civil constructi work, purchase of equipment, plant and machinery for setting up New manufacturing line for SVP at Hariyala, Kheda, Gujarat. | 30.13 | 7.46 | No |
| Public IssuesSep 2025, checked by CRISIL Ratings Limited | 126.00 | General corporate purposes | 3.02 | 3.02 | No |
| Public IssuesSep 2025, checked by CRISIL Ratings Limited | 126.00 | Issue Expenses | 22.85 | 22.85 | No |